148 related articles for article (PubMed ID: 36649984)
21. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence.
Chu KP; Baker S; Zenke J; Morad A; Ghosh S; Morrish DW; McEwan AJBS; Williams DC; Severin D; McMullen TPW
Thyroid; 2018 Jul; 28(7):902-912. PubMed ID: 29742993
[TBL] [Abstract][Full Text] [Related]
22. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
[TBL] [Abstract][Full Text] [Related]
23. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
Ma C; Xie J; Chen Q; Wang G; Zuo S
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007956. PubMed ID: 19821441
[TBL] [Abstract][Full Text] [Related]
24. Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer.
Riesco-Eizaguirre G; Galofré JC; Grande E; Zafón Llopis C; Ramón y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Capdevila J
Endocrinol Nutr; 2016 Apr; 63(4):e17-24. PubMed ID: 26601805
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.
Ma C; Kuang A; Xie J
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD006988. PubMed ID: 19160311
[TBL] [Abstract][Full Text] [Related]
26. [Chinese expert consensus on the pelvic exenteration for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition)].
; ;
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):16-26. PubMed ID: 36649995
[TBL] [Abstract][Full Text] [Related]
27. Radioactive iodine therapy in poorly differentiated thyroid cancer.
Tuttle RM; Grewal RK; Larson SM
Nat Clin Pract Oncol; 2007 Nov; 4(11):665-8. PubMed ID: 17965644
[TBL] [Abstract][Full Text] [Related]
28. Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.
Zhu Y; Liu K; Wang K; Peng L
Front Endocrinol (Lausanne); 2022; 13():909333. PubMed ID: 35909569
[TBL] [Abstract][Full Text] [Related]
29. Differential distribution and prognostic value of CD4
Shi ZY; Zhang SX; Li CH; Fan D; Xue Y; Cheng ZH; Wu LX; Lu KY; Wu ZF; Li XF; Liu HY; Li SJ
Front Immunol; 2022; 13():966550. PubMed ID: 36091039
[TBL] [Abstract][Full Text] [Related]
30. [Indications for and against the treatment of thyroid cancer with radioactive iodine].
Wieckowski B; Skrzypek J
Pol Tyg Lek; 1983 Apr; 38(16):501-3. PubMed ID: 6634495
[No Abstract] [Full Text] [Related]
31. [CME: Radioactive iodine therapy in thyroid cancer].
Steinert HC; Aberle S
Praxis (Bern 1994); 2015 Nov; 104(23):1235-43; quiz 1244-5. PubMed ID: 26558927
[TBL] [Abstract][Full Text] [Related]
32. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.
Sawka AM; Thephamongkhol K; Brouwers M; Thabane L; Browman G; Gerstein HC
J Clin Endocrinol Metab; 2004 Aug; 89(8):3668-76. PubMed ID: 15292285
[TBL] [Abstract][Full Text] [Related]
33. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures.
Reiners C; Dietlein M; Luster M
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):989-1007. PubMed ID: 19041827
[TBL] [Abstract][Full Text] [Related]
34. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131).
Coburn M; Teates D; Wanebo HJ
Ann Surg; 1994 Jun; 219(6):587-93; discussion 593-5. PubMed ID: 8203968
[TBL] [Abstract][Full Text] [Related]
35. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).
Capdevila J; Galofré JC; Grande E; Zafón Llopis C; Ramón Y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Riesco Eizaguirre G
Clin Transl Oncol; 2017 Mar; 19(3):279-287. PubMed ID: 27704399
[TBL] [Abstract][Full Text] [Related]
36. Perspective: The Molecular Landscape of Radioactive Iodine Refractory Differentiated Thyroid Cancer and Poorly Differentiated Thyroid Cancer.
Shobab L; Wartofsky L
Thyroid; 2023 Feb; 33(2):138-142. PubMed ID: 36345225
[No Abstract] [Full Text] [Related]
37. Iodine-125 radioactive seed tissue implantation as a remedy treatment for recurrent cervical cancer.
Han L; Li C; Wang J; He X; Zhang X; Yang J; Liu G
J Cancer Res Ther; 2016 Dec; 12(Supplement):C176-C180. PubMed ID: 28230013
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic Effect of CT-guided ¹²⁵I Seed Implantation on Advanced Lung Cancer and Pulmonary Metastatic Carcinoma].
Wang Y; Zhu L; Lin X; He C; An Z; Tang J; Lv W; Hu J
Zhongguo Fei Ai Za Zhi; 2020 Jun; 23(6):424-428. PubMed ID: 32517444
[TBL] [Abstract][Full Text] [Related]
39. Radioiodine Refractory Differentiated Thyroid Cancer.
Chan WWL; Chan S; Kwong DLW
Methods Mol Biol; 2022; 2534():243-257. PubMed ID: 35670980
[TBL] [Abstract][Full Text] [Related]
40. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
